Maya Gottfried
Overview
Explore the profile of Maya Gottfried including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
9050
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marabelle A, OMalley D, Hendifar A, Ascierto P, Motola-Kuba D, Penel N, et al.
Nat Cancer
. 2025 Feb;
6(2):253-258.
PMID: 39979665
The phase 2 trial KEYNOTE-158 ( NCT02628067 ) evaluated pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient (MSI-H/dMMR) noncolorectal tumors. With 373 participants (95% with baseline MSI/dMMR documentation) and 4.5 years of follow-up,...
2.
Christopoulos P, Harel M, McGregor K, Brody Y, Puzanov I, Bar J, et al.
JCO Precis Oncol
. 2024 Mar;
8:e2300555.
PMID: 38513170
Purpose: Current guidelines for the management of metastatic non-small cell lung cancer (NSCLC) without driver mutations recommend checkpoint immunotherapy with PD-1/PD-L1 inhibitors, either alone or in combination with chemotherapy. This...
3.
Bar J, Leibowitz R, Reinmuth N, Ammendola A, Jacob E, Moskovitz M, et al.
Front Immunol
. 2024 Mar;
15:1364473.
PMID: 38487531
Introduction: Immune checkpoint inhibitors have made a paradigm shift in the treatment of non-small cell lung cancer (NSCLC). However, clinical response varies widely and robust predictive biomarkers for patient stratification...
4.
Bar J, Esteban E, Rodriguez-Abreu D, Aix S, Szalai Z, Felip E, et al.
Lung Cancer
. 2024 Feb;
190:107506.
PMID: 38422883
Background: First-line pembrolizumab plus chemotherapy has shown clinical benefit in patients with metastatic non-small cell lung cancer (NSCLC) regardless of tissue tumor mutational burden (tTMB) status. Blood tumor mutational burden...
5.
Kim H, Awad M, Navarro A, Gottfried M, Peters S, Csoszi T, et al.
JTO Clin Res Rep
. 2023 Nov;
4(11):100572.
PMID: 37954964
Introduction: In the phase 3 KEYNOTE-604 study (NCT03066778), pembrolizumab plus etoposide and platinum chemotherapy (EP) significantly ( = 0.0023) improved progression-free survival versus placebo plus EP in previously untreated extensive-stage...
6.
Reck M, Popat S, Grohe C, Corral J, Novello S, Gottfried M, et al.
Lung Cancer
. 2023 Mar;
179:107173.
PMID: 36940614
The implementation of immune checkpoint inhibitors (ICIs), with or without chemotherapy, as first-line treatment for patients who do not have actionable mutations has proved to be a major paradigm shift...
7.
Maio M, Amonkar M, Norquist J, Ascierto P, Manzyuk L, Motola-Kuba D, et al.
Eur J Cancer
. 2022 May;
169:188-197.
PMID: 35588692
Background: In the KEYNOTE-158 study (NCT02628067), pembrolizumab showed a high objective response rate and durable clinical benefit for patients with previously treated, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair‒deficient (dMMR) non-colorectal solid...
8.
Moskovitz M, Dudnik E, Shamai S, Rotenberg Y, Popovich-Hadari N, Wollner M, et al.
Oncologist
. 2022 Mar;
27(1):e76-e84.
PMID: 35305096
Objectives: ALK inhibitors (ALKi) are the standard-of-care treatment for metastatic ALK-rearranged non-small cell lung cancer (NSCLC) in the first- and second-line setting. We conducted a real-world multi-institutional analysis, aiming to...
9.
Hirsh-Yechezkel G, Chetrit A, Avraham S, Agbarya A, Yakobson A, Asna N, et al.
Isr Med Assoc J
. 2021 Dec;
23(12):759-765.
PMID: 34954913
Background: The increased susceptibility of cancer patients to coronavirus disease-2019 (COVID-19) infections and complications calls for special precautions while treating cancer patients during COVID-19 pandemics. Thus, oncology departments have had...
10.
Le X, Sakai H, Felip E, Veillon R, Garassino M, Raskin J, et al.
Clin Cancer Res
. 2021 Nov;
28(6):1117-1126.
PMID: 34789481
Purpose: Primary analysis of VISION showed tepotinib had durable clinical activity in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC). We present updated outcomes for clinically...